Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study

• Published in: Diabetology and metabolic syndrome 2019-01, Vol.11 (1), p.3-3, Article 3
• Main Authors: Watanabe, Jun, Kakehi, Eiichi, Kotani, Kazuhiko, Kayaba, Kazunori, Nakamura, Yosikazu, Ishikawa, Shizukiyo
• Format: Article
• Language: English
• Subjects: Alcohol; Blood pressure; Cancer; Cancer research; Cardiovascular disease; Cohort analysis; Cohort studies; Complications and side effects; Death; Diabetes; Drinking (Alcoholic beverages); Drinking behavior; Education; Educational attainment; Epidemiology; Family medical history; Health risk assessment; Heart; Hypertension; Japanese; Marital status; Marriage; Medical research; Medical schools; Menopause; Metabolic syndrome; Metabolic syndrome X; Mortality; Municipal government; Neoplasm; Obesity; Occupations; Physical activity; Population; Public health; Questionnaires; Regression analysis; Risk factors; Secondary schools; Smoking; Task forces; Tumors; Women; Womens health
• ISSN: 1758-5996; 1758-5996
• DOI: 10.1186/s13098-018-0398-2

Metabolic syndrome (MetS) and cancer are major public health problems worldwide. The relationship between MetS and cancer death is of great interest. We examined the predictive value of MetS for cancer mortality in Japan. Study participants included 4495 men and 7028 women aged 18-90 years who were registered between 1992 and 1995 as part of the Jichi Medical School Cohort Study. We used a definition of MetS modified for the Japanese population. The primary outcome was cancer mortality. Additionally, the relationship between MetS and cancer-type specific mortality was examined. Analyses were conducted with Cox's regression models adjusted for age, smoking status, alcohol drinking status, marital status, educational attainment, physical activity, occupational category, and menopausal status (only in women). During a mean follow-up of 18.5 years, 473 men and 297 women died from cancer. MetS was positively associated with cancer mortality in women (hazard ratio [HR], 1.69; 95% confidence interval [CI] 1.21-2.36), but not in men (HR, 1.21; 95% CI 0.90-1.62). Additionally, MetS was associated with a high risk of colorectal (HR, 3.48; 95% CI 1.68-7.22) and breast (HR, 11.90; 95% CI 2.25-62.84) cancer deaths in women. MetS was a significant predictor of cancer mortality in women.